SUMMARY Long term perhexiline maleate therapy causes peripheral neuropathy and hepatic damage in certain subjects. An association between these adverse reactions and a genetically determined relative inability to hydroxylate debrisoquine has been described. This association could indicate either that the effects of perhexiline impair debrisoquine oxidation thus producing a phenocopy, or that perhexiline is polymorphically hydroxylated and that the polymorphism is controlled by the same alleles as control the debrisoquine polymorphism. To test the second possibility, a study investigating the hydroxylation status of a population of healthy volunteer subjects has teen performed using perhexiline maleate.
Patients developing peripheral neuropathy exhibit greater plasma perhexiline levels with prolonged plasma half lives when compared with non-neuropathic patients on equivalent oral dosage.15 Neuro- The details for the preparation of the samples for gas chromatographic analysis are shown in appendix 1 and the details of the gas liquid chromatograph (GLC) in appendix 2. The limits of detection were comparable to other methods currently available. 24 All results were verified by integrated gas chromatography/mass spectrometry using both VG70/70F (Vacuum Gases) and AEI MS12 (Kratos) equipment.
Previous debrisoquine population studies'6 I7 have described oxidation capacity using the urinary metabolic ratio calculated as follows: Low values (<1) represent extensive oxidisers while high values (>12-5) represent grossly impaired oxidisers. The urinary excretion of unchanged perhexiline after a single oral dosage is so small that calculation of a urinary metabolic ratio is not feasible. Urinary excretion rates for MI and MIII metabolites were expressed as ,ug excreted during the 12 to 24 hour urine collection period.
Plasma concentrations and urinary excretion data were used to compare oxidation ability in the 50 volunteers and the six subjects of known oxidation status.
Results
In the following data the mean value ±SD is given in each instance. The population who had not been previously phenotyped consisted of healthy medical students and nursing and laboratory staff. Twentyeight males were studied aged 22±5-4 years with a height of I) .
The 24-hour plasma perhexiline concentration was 0 072±0 04 FLg/ml in the 47 extensive oxidisers while the three poor oxidisers gave a value of 0 43±0 065 ,ug/ml(fig2;t=8.7,df48,p<0.001).
rs (47) The three previously phenotyped poor oxidisers of (3) debrisoquine and sparteine were also found to be poor oxidisers of perhexiline, while the three known extensive oxidisers of debrisoquine and sparteine were also found to be extensive oxidisers of perhexiline (table 1, fig 1) . Plasma MIII metabolite was virtually undetectable. Urinary excretion of MIII was 1515±1003 ,ug in the 12 to 24 hour period in extensive metabolisers and 671 ±288 ,ug in the three poor producers of the MI metabolite, thus demonstrating no significant difference between the phenotypes with regard to MIII production. There is no bimodal distribution of MIII metabolite excretion (fig 3) .
When the urinary excretion of metabolites in the 12 to 24 hour period is expressed as a percentage of The use of perhexiline maleate for population oxidation phenotyping has given direct rather than inferred information about perhexiline hydroxylation. By testing healthy subjects on no current drug treatments, the element of doubt about hepatic dysfunction due to perhexiline or other drugs is excluded. Conclusive evidence for polymorphism has been provided by the bimodal distribution of plasma perhexiline concentration, plasma Ml metabolite concentration, and urinary MI metabolite excretion (fig 1) . Known poor oxidisers of debrisoquine and sparteine are also poor oxidisers of perhexiline, and known extensive oxidisers of debrisoquine and sparteine are also extensive oxidisers of perhexiline (table 1, fig 1) . The genetic control of perhexiline hydroxylation polymorphism is, therefore, identical in white British subjects to that for debrisoquine and other compounds (for example, sparteine). A genetic relative inability to oxidise debrisoquine, sparteine, and now perhexiline has been demonstrated. This inherited 'defect' may not apply to all drug oxidations.31 Perhexiline phenotyping has shown that both extensive and severely impaired producers of 4-monohydroxyperhexiline (MI metabolite) can produce and excrete similar amounts of 4'-monohydroxyperhexiline (MIII metabolite), thus demonstrating a stereotactic substrate preference for oxidation by a hepatic cytochrome P-450.
Perhexiline phenotyping distinguishes subjects with impaired oxidation governed by the debrisoquine type DHDL allele genetic system more clearly than debrisoquine or other tests. It defines clearly those at risk from accumulation of perhexiline, debrisoquine, and therefore other drugs controlled by the same alleles. Consequently, it may well be a useful tool for excluding those at risk from the dangerous toxic side effects of these compounds.
